[1] Friedman SL.Evolving challenges in hepaticfibrosis.Nat Rev Gastroenterol Hepatol,2010,7:425-436.
[2] Wai CT,Greenson JK,Fontana RJ,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003,38:518-526.
[3] Ma J,Jiang Y,Gong G.Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol, 2013,25:428-434.
[4] 周青青,胡益冰,周克,等.肝纤维化无创模型对丙氨酸氨基转移酶低于2倍正常值上限慢性乙型肝炎患者治疗时机的判定价值.中华肝脏病杂志,2016,24:665-670.
[5] Jin W,Lin Z,Xin Y,et al.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol, 2012,12:14.
[6] 乐萍,高国生,董飞波,等.血清高尔基体蛋白73及3种评分系统对慢性乙型肝炎患者肝纤维化的预测价值研究.中华医院感染学杂志,2016,26:2529-2531.
[7] Sterling RK,Lissen E,Clumeck N,et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006,43:1317-1325.
[8] Zhang Z,Wang G,Kang K,et al. The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection. PLoS One, 2016,11:e0152757.
[9] Ding D,Li H,Liu P,et al.FibroScan,aspartate aminotransferase and alanine aminotransferase ratio (AAR),aspartate aminotransferase to platelet ratio index (APRI),fibrosis index based on the 4 factor (FIB-4),and their combinations in the assessment of liver fibrosis in patients with hepatitis B. Int J Clin Exp Med, 2015,8:20876-20882.
[10] Yang L,Ding Y,Rao S,et al.Staging liver fibrosis in chronic hepatitis B with T1 relaxation time index on gadoxetic acid-enhanced MRI:Comparison with aspartate aminotransferase-to-platelet ratio index and FIB-4. J Magn Reson Imaging, 2017,45:1186-1194.
[11] Forns X,Ampurdanes S,Llovet JM,et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002,36(4 Pt 1):986-992.
[12] Dong CF,Xiao J,Shan LB,et al.Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B. World J Hepatol, 2016,8:616-624.
[13] Dong DR,Hao MN,Li C,et al.Acoustic radiation force impulse elastography, FibroScan(R), Forns′ index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B,and the impact of inflammatory activity and steatosis on these diagnostic methods. Mol Med Report, 2015,11:4174-4182.
[14] Zhuang Y,Ding H,Zhang Y,et al. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B:comparison with serum fibrosis indexes. Radiology, 2017,283:873-882.
[15] Cales P,Oberti F,Michalak S,et al.A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 2005,42:1373-1381.
[16] Mbaye PS,Sarr A,Sire JM,et al. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. PLoS One, 2011,6:e22291.
[17] Chen YP,Peng J,Hou JL.Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int, 2013,7:356-368.
[18] Imbert-Bismut F,Ratziu V,Pieroni L,et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:a prospective study. Lancet, 2001,357:1069-1075.
[19] Houot M,Ngo Y,Munteanu M,et al.Systematic review with meta-analysis:direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther,2016,43:16-29.
[20] Poynard T,Munteanu M,Deckmyn O,et al.Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol, 2012,57:541-548.
[21] Wang C,Cheng X,Meng C,et al. Diagnostic value of FibroTest for liver fibrosis in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi, 2015,23:738-741.
[22] Cheng J,Hou J,Ding H,et al.Validation of ten noninvasive diagnostic models for prediction of liver fibrosis in patients with chronic hepatitis B. PLoS One, 2015,10:e0144425.
[23] Zeng MD,Lu LG,Mao YM,et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology, 2005,42:1437-1445.
[24] 周琨,郑瑞丹,咸建春,等.从常规指标中建立肝纤维化非创伤性诊断模型.肝脏,2008,13:362-367.
[25] Liu WP,Xu DJ,Zhao LR,et al. The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B. Zhonghua Nei Ke Za Zhi, 2008,47:308-312.
[26] Hui AY,Chan HL,Wong VW,et al.Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol, 2005,100:616-623.
[27] 张文胜,王宝恩,王泰龄,等.慢性乙型肝炎肝纤维化无创性诊断模型的建立.中华肝脏病杂志,2006,14:169-173.
[28] 吴盛迪,刘黎黎,李蕾,等.慢性乙型肝炎患者肝纤维化无创诊断模型的建立和验证.中华消化杂志,2010,30:478-480.
[29] 宛瑞杰. 慢性HBV感染者无创诊断模型的建立及病证结合抗肝纤维化临床研究. 北京中医药大学,2012.
[30] 唐情容,何清,廖雪姣,等.ALT<2倍ULN慢性乙型肝炎肝纤维化非创性评分模型的建立.中国病毒病杂志,2015,5:125-129. |
